SynDevRx Inc.
This article was originally published in Start Up
Executive Summary
The lead candidate of SynDevRx is a validated anti-angiogenic small molecule, developed at the lab of Judah Folkman, conjugated to a polymer delivery system. It binds to MetAP2, a target that helps regulate blood vessel structure and permeability. When overexpressed, it helps to signal the formation of the new blood vessels that help sustain nutrient-starved tumors, and also plays a role in regulating programmed cell death.